Ifosfamide in pediatric malignancies - PubMed

Affiliations

• PMID: 2649985

Review

Ifosfamide in pediatric malignancies

H Jürgens et al. Semin Oncol. 1989 Feb.

Abstract

In pediatric malignancies, particularly sarcomas, alkylating agents play an important role in the curative, combination chemotherapy approach. Since high doses of ifosfamide, the structural isomer of cyclophosphamide, were made tolerable with mesna uroprotection, high-dose ifosfamide (5 to 10 g/m2) has replaced conventional-dose cyclophosphamide (900 to 1,500 mg/m2) in some combination chemotherapy regimens. In Ewing's sarcoma and soft tissue sarcoma, the response rate and proportion of patients surviving disease free have been increased (at least for poor-prognosis patients) by 15% to 20% with an ifosfamide-containing regimen, as used in ongoing trials of the German Society of Pediatric Oncology. In germ cell tumors, the combination of ifosfamide and etoposide has proved to be an effective salvage regimen in patients resistant to vinblastine, bleomycin, and cisplatin. In stage IV disseminated neuroblastoma, however, the introduction of ifosfamide-containing regimens has not altered the poor prognosis. Results reflecting the value of ifosfamide in osteosarcoma, Wilms' tumor and Hodgkin's and non-Hodgkin's lymphomas are pending. It is not yet known whether high doses of akylating agents will increase the risk of late sequelae in cured patients.

Similar articles

• Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

  Hagemeister FB. Hagemeister FB. Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12. Cancer Chemother Pharmacol. 2002. PMID: 12042984 Review.

• Ifosfamide in the treatment of pediatric malignancies.

  Voûte PA, van den Berg H, Behrendt H, Michiels E, de Kraker J. Voûte PA, et al. Semin Oncol. 1996 Jun;23(3 Suppl 7):8-11. Semin Oncol. 1996. PMID: 8711502

• [Ifosfamide in pediatric malignancy--experiences in the Northern Israel Oncology Center].

  Roguin A, Ben Arush MW, Higasi A, Kuten A. Roguin A, et al. Harefuah. 1996 Apr 15;130(8):511-4, 584. Harefuah. 1996. PMID: 8765870 Hebrew.

• Phase II trial of ifosfamide in children with malignant solid tumors.

  Pratt CB, Horowitz ME, Meyer WH, Etcubanas E, Thompson EI, Douglass EC, Wilimas JA, Hayes FA, Green AA. Pratt CB, et al. Cancer Treat Rep. 1987 Feb;71(2):131-5. Cancer Treat Rep. 1987. PMID: 3100034

• The role of ifosfamide in the treatment of sarcomas.

  Dirix LY, Van Oosterom AT. Dirix LY, et al. Semin Oncol. 1989 Feb;16(1 Suppl 3):39-45. Semin Oncol. 1989. PMID: 2649984 Review.

Cited by

• Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.

  Boos J, Welslau U, Ritter J, Blaschke G, Schellong G. Boos J, et al. Cancer Chemother Pharmacol. 1991;28(6):455-60. doi: 10.1007/BF00685822. Cancer Chemother Pharmacol. 1991. PMID: 1934249

• In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro.

  Yaseen Z, Michoudet C, Baverel G, Dubourg L. Yaseen Z, et al. Pediatr Nephrol. 2008 Apr;23(4):611-8. doi: 10.1007/s00467-007-0689-6. Epub 2008 Jan 18. Pediatr Nephrol. 2008. PMID: 18204866

• Isolation of circulating tumor cells in a preclinical model of osteosarcoma: Effect of chemotherapy.

  Chalopin A, Tellez-Gabriel M, Brown HK, Vallette F, Heymann MF, Gouin F, Heymann D. Chalopin A, et al. J Bone Oncol. 2018 Jul 26;12:83-90. doi: 10.1016/j.jbo.2018.07.002. eCollection 2018 Sep. J Bone Oncol. 2018. PMID: 30123735 Free PMC article.

• The impact of intraoperative brachytherapy on surgery of Ewing's sarcoma.

  Ozaki T, Hillmann A, Rübe C, Rödl R, Hein M, Hoffmann C, Blasius S, Jürgens H, Winkelmann W. Ozaki T, et al. J Cancer Res Clin Oncol. 1997;123(1):53-6. doi: 10.1007/BF01212615. J Cancer Res Clin Oncol. 1997. PMID: 8996541 Clinical Trial.

• Heterogeneous Circulating Tumor Cells in Sarcoma: Implication for Clinical Practice.

  Agnoletto C, Caruso C, Garofalo C. Agnoletto C, et al. Cancers (Basel). 2021 May 2;13(9):2189. doi: 10.3390/cancers13092189. Cancers (Basel). 2021. PMID: 34063272 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Medical

  • MedlinePlus Health Information